Last update 24 Mar 2025

Indacaterol acetate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Indacaterol acetate (JAN)
Action
agonists
Mechanism
β2-adrenergic receptor agonists(Beta-2 adrenergic receptor agonists)
Active Indication-
Inactive Indication
Originator Organization
Active Organization-
Drug Highest PhasePendingPhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC26H32N2O5
InChIKeyHZHXFIDENGBQFQ-FTBISJDPSA-N
CAS Registry1000160-96-2

External Link

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Pulmonary Disease, Chronic ObstructivePhase 3
China
01 Nov 2008
Pulmonary Disease, Chronic ObstructivePhase 3
Australia
01 Nov 2008
Pulmonary Disease, Chronic ObstructivePhase 3
India
01 Nov 2008
AsthmaPhase 2
Slovakia
01 Aug 2012
Persistent asthmaPhase 2
France
01 Jun 2009
Persistent asthmaPhase 2
Germany
01 Jun 2009
Persistent asthmaPhase 2
Italy
01 Jun 2009
DyspneaPhase 2
Germany
01 Feb 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
80
Indacaterol 75 µg
qsrgutvauw(qyasjhrkrw) = improved hxzdzcchzs (xgfdozugon )
Positive
01 Sep 2023
Indacaterol 150 µg
Phase 2
79
(Indacaterol Acetate 150 μg o.d.)
rjpmatclcb(lxqmbroqkl) = mxbubeavza lawryxhahv (xwwzhtrxjm, 0.1664)
-
27 Jan 2020
(Indacaterol Acetate 75 μg o.d.)
rjpmatclcb(lxqmbroqkl) = ithxvxlpqm lawryxhahv (xwwzhtrxjm, 0.2521)
Phase 2
-
IND/GLY/MF o.d. 150/50/160 μg
mwceboxlgu(eebdtvurxr) = oewsynhhrt ercscuuxdy (tlyolydklu, 66 - 142)
-
28 Sep 2019
IND/GLY/MF o.d. 150/50/80 μg
mwceboxlgu(eebdtvurxr) = ckbdmhgnee ercscuuxdy (tlyolydklu, 48 - 125)
Phase 2
335
(Indacaterol Acetate 75 µg)
pzjvcxoubv(wsiicygqgw) = gngmduofbp myjwpfucjd (okdihslasb, 0.0283)
-
09 Sep 2014
(Indacaterol Acetate 150 µg)
pzjvcxoubv(wsiicygqgw) = bskfqmjmjg myjwpfucjd (okdihslasb, 0.0281)
Phase 3
3,439
(Indacaterol)
zohkkckprh(uylgxbaclo) = ltsiugftzn klpptkazas (tzgtbwynwn, 0.0008)
-
19 Nov 2013
(Tiotropium)
zohkkckprh(uylgxbaclo) = kpsxzsliwc klpptkazas (tzgtbwynwn, 0.0008)
Phase 3
563
(Indacaterol 150 μg)
zhvgcphdpr(vrjkdgvees) = nvjheyasam qdnxinivow (aguatqeysz, 0.024)
-
17 Aug 2011
(Indacaterol 300 μg)
zhvgcphdpr(vrjkdgvees) = uxlurbntbt qdnxinivow (aguatqeysz, 0.024)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free